Last reviewed · How we verify
Quetiapine Immediate Release
Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Quetiapine Immediate Release |
|---|---|
| Also known as | Seroquel IR |
| Sponsor | AstraZeneca |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which are implicated in psychosis and mood dysregulation. It also has activity at other receptors including histamine H1 and adrenergic receptors, contributing to its sedating properties and broader psychiatric effects.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Major depressive disorder (adjunctive treatment)
- Generalized anxiety disorder
Common side effects
- Somnolence/sedation
- Dry mouth
- Dizziness
- Headache
- Weight gain
- Orthostatic hypotension
- Tachycardia
Key clinical trials
- Standardized Sleep Bundle for Cardiac Surgery Patients (NA)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (PHASE4)
- Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation (PHASE1)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine (PHASE2)
- A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety (PHASE4)
- Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quetiapine Immediate Release CI brief — competitive landscape report
- Quetiapine Immediate Release updates RSS · CI watch RSS
- AstraZeneca portfolio CI